Dermatomiositis, enfermedad reumática con manifestaciones cutáneas
Keywords:
dermatomiositis, miopatías inflamatorias idiopáticas, manifestación cutánea, afectación de la pielAbstract
Introducción: las miopatías inflamatorias idiopáticas son enfermedades autoinmunes raras que afectan principalmente al músculo esquelético, pudiendo también afectar a otros órganos y tejidos. La dermatomiositis es una de las subcategorías de las miopatías inflamatorias idiopáticas que presenta manifestaciones cutáneas.
Objetivo: describir aspectos generales del conocimiento actual sobre el diagnóstico, etiología y manifestaciones clínicas de la dermatomiositis, con énfasis en las cutáneas por la significación que tienen para los pacientes.
Desarrollo: la dermatomiositis es una enfermedad muscular y cutánea adquirida que forma parte de las miopatías inflamatorias idiopáticas. Existen variantes clínicas de la enfermedad. El diagnóstico se basa en la historia clínica, examen físico y pruebas de laboratorio.
Conclusiones: la dermatomiositis es una enfermedad rara que forma parte de las miopatías inflamatorias idiopáticas. Se caracteriza por debilidad muscular, erupción cutánea y puede afectar a otros órganos. Existe un mayor riesgo de desarrollar neoplasias en pacientes con dermatomiositis. Se investiga el uso de autoanticuerpos como posibles marcadores en el diagnóstico.
Downloads
References
Mariampillai K, Granger B, Amelin D, Guiguet M, Hachulla E, Maurier F, Meyer A, Tohme A, Charuel JL. (2018). Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies. JAMA Neurol.75, 1528-1537.
Shu Y, Christopher Ch, Zhe L. (2019). Polymyositis and dermatomyositis – challenges in diagnosis and management, Journal of Translational Autoimmunity, 2. 100018, ISSN 2589-9090, https://doi.org/10.1016/j.jtauto.2019.100018.
Kamperman RG, van der Kooi AJ, de Visser M, Aronica E, Raaphorst J. (2022). Pathophysiological Mechanisms and Treatment of Dermatomyositis and Immune Mediated Necrotizing Myopathies: A Focused Review. Int. J. Mol. Sci. 2022, 23, 4301. https://doi.org/10.3390/ ijms23084301
Ahmed M, Machado PM, Miller A, et al. (2016). Targeting protein homeostasis in sporadic inclusion body myositis. Sci Transl Med; 8:331ra41.
Allenbach Y, Mammen AL, Benveniste O, Stenzel W. (2018). Immune-Mediated Necrotizing Myopathies Working Group. 224th ENMC International Workshop: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016. Neuromuscul. Disord. 28, 87-99
Hoogendijk JE, et al. (2004). 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands, Neuromuscul. Disord. 14 (5) 337-345.
Dalakas MC, Hohlfeld R. (2003). Polymyositis and dermatomyositis, Lancet 362 (9388) 971-982.
Castro C, Gourley M. (2012). Diagnosis and treatment of inflammatory myopathy: issues and management. Ther Adv Musculoskelet Dis 4 (2) 111-120.
Mammen AL, Allenbach Y, Stenzel W, Benveniste O. (2020). ENMC 239th
Workshop Study Group. 239th ENMC International Workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14-16 December 2018. Neuromuscul. Disord. 30, 70-92.
Dalakas MC. (2015). Inflammatory muscle diseases, N. Engl. J. Med. 372 (18) 1734-47.
Satoh M, Tanaka S, Ceribelli A, Calise SJ, Chan EK. (2017). A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy. Clin Rev Allergy Immunol. 52(1):1-19.
Briani C, Doria A, Sarzi-Puttini P, Dalakas MC. (2006). Update on idiopathic inflammatory myopathies. Autoimmunity. May;39(3):161-70.
Gerami P, Schope JM, McDonald L, Walling HW, Sontheimer RD. (2006). A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis siné myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol. Apr;54(4):597-613.
Lundberg IE, Fujimoto M, Vencovsky J, Aggarwal R, Holmqvist M, Christopher L, Mammen AL, Miller FW. (2021). Idiopathic inflammatory myopathies. Nat. Rev. Dis. Primers, 7, 86.
Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, Evans SR, Felson DT. (2001). Frequency of specific cancer types in dermatomyositis and polymyositis: A population-based study. Lancet, 357, 96-100.
Callen J. (2002). When and how should the patient with dermatomyo- sitis or amyopathic dermatomyositis be assessed for possible cancer? Arch Dermatol. 138:969-71.
Schmidt J. (2018). Current Classification and Management of Inflammatory Myopathies. J. Neuromuscul. 5, 109-129.
Tanboon J, Uruha A, Stenzel W, Nishino I. (2020). Where are we moving in the classification of idiopathic inflammatory myopathies? Curr. Opin. Neurol. 33, 590-603.
Adler BL, Christopher-Stine L. (2018). Triggers of inflammatory myopathy: insights into pathogenesis. Discov Med. Feb;25(136):75-83.
Kimyai A, Tausk FA, Nousari HC. (2000). A patient with dermatomyositis and linear streaks on the back. Arch Dermatol, 136, pp. 665-670.
Polo I, Medina S, Trasobares L, Bohórquez C. (2017). Manifestaciones cutáneas de las enfermedades reumatológicas. Medicine. 12(26):1520-9. DOI:10.1016/j.med.2017.01.013
Callen JP. (2010). Cutaneous manifestations of dermatomyositis and their management. Curr Rheumatol Rep; 12:192.
Scrivener Y, El Aboubi-Kuhne, Marquart-Elbaz C, Cribier B. (1999). Diagnostic d’un oedeme orbito-palpebral. Ann Dermatol Venereol. 126:844-8.
Restrepo1 LF, Medina F, Molina MP. (2020). Manifestaciones cutáneas de la dermatomyositis. Rev Asoc Colomb Dermatol. 18: 18-24.
Bielsa I. (2009). Dermatomiositis. Reumatol Clin. 5(5):216-222.
Vattemi G, Mirabella M, Guglielmi V, Lucchini M, Tomelleri G, Ghirardello A, Doria A. (2014). Muscle biopsy features of idiopathic inflammatory myopathies and differential diagnosis. Auto Immun Highlights. 5(3):77-85.
Smith ES, Hallman JR, DeLuca AM, Goldenberg G, Jorizzo JL, Sangueza OP. (2009). Dermatomyositis: a clinicopathological study of 40 patients. Am J Dermatopathol. 31(1):61-7.
Fredi, M, Cavazzana I, Franceschini F. (2018). The clinico-serological spectrum of overlap myositis. Curr. Opin. Rheumatol. 30, 637-43.
Downloads
Published
How to Cite
Issue
Section
License
Warning of rights of author
The authors that publish in this journal agree with the following terms:
The authors conserve the rights of author and concede to the journal the right of the first publication, fulfilling with the license Creative Commons Attribution License that allows to others share the work with recognition of the authorship of their articles, and the initial publication in this journal.
The authors can establish separately additional agreements for the no exclusive distribution of the version of the work published in the journal (for example, situate it in an institutional repository, in a personal blog or publish it partial or totally in a book), with a recognition of their initial publication in this journal.
To be able to send the manuscript or part of him passed three months of published, for his evaluation to other publishers, identifying it or not with the same title; whenever allusion is made to our journale and know it the new publisher.
The publishing committee of the Cuban Journal of Rheumatology authorizes to other publishers, to reproduce the articles published in our magazine, whenever it indicate the origin of the same.
The authors should send a document in Office Word application format through the electronic address of the magazine with a similar format to that we include next:
---------------------------------------------------------------------------------------------------------------------
Statement of authorship and cede of articles for the publication of the scientific work in the Cuban Journal of Rheumatology
Date:
Those who subscribe certify that are the authors of the work:
Of this form communicate the originality of our article clearing that the concepts and knowledges of other authors that have included in the text of the article, have been quoted properly in the bibliography.
We do proof besides that the article in question is original and has not been published, total neither partially, in another journal.
To be approved for his publication in the Cuban Journal of Rheumatology, do secession of the rights of publication to the same one through the method that realizes it usually.
In front of any catchword that exist by the article that send to evaluate, relieve of of the responsibility to the Cuban Journal of Rheumatology holding us responsible with all the difficulties that can berelated by any situation.
We include to continuation the name and the signature of all authors and collaborators of this article.
Name: Signature:
